Xintela

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

The Group
Third quarter 2025
Income amounted to TSEK 855 (2,822).
Loss before tax totalled TSEK 10,035 (loss: 8,049).
Loss per share was SEK 0.01 (loss: 0.01).
 
First nine month of 2025
Income amounted to TSEK 1,867 (3,125).
Loss before tax totalled TSEK 32,816 (loss: 29,821).
Loss per share was SEK 0.05 (loss: 0.05).
 
The Parent Company
Third quarter 2025
Income amounted to TSEK 855 (2,822).
Loss before tax totalled TSEK 7,741 (loss: 5,971).
 
First nine month of 2025
Income amounted to TSEK 1,867 (3,125).
Loss before tax totalled TSEK 27,027 (loss: 24,225).
 
 
Significant events in the second quarter of 2025
· Xintela AB announces that the company is changing its Certified Adviser to Tapper Partners AB.
· Xintela strengthens management team with the appointment of Peter Ekolind as COO & VP Commercial Manufacturing
· Xintelas announces that the final evaluation of XSTEM in the knee osteoarthritis clinical study, 24 months after treatment, has now been completed. The results show continued safety, reduction in knee pain, improved joint function and improved cartilage and bone structure. This confirms a lasting treatment effect and provides support for a disease-modifying effect of XSTEM.
 
Significant events after the end of the period
· Xintela announces that Xintela's oncology subsidiary, Targinta AB, has entered into a collaboration with Memorial Sloan Kettering Cancer Center's (MSK) Therapeutics Accelerator in New York, USA, for the clinical development of integrin α10β1-targeted antibodies for the treatment of patients with aggressive sarcoma.

The complete report is available for download below and on the company’s website www.xintela.se/en/report-archive.